Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti–Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody

Sara Traini1,2, Enza Piccolo1,2, Nicola Tinari1,2, Cosmo Rossi2, Rossana La Sorda1,2, Francesca Spinella3, Anna Bagnato3, Rossano Lattanzio3, Maurizia D’Egidio1,2, Annalisa Di Risio1,2, Federica Tomao4, Antonino Grassadonia2, Mauro Piantelli1,2, Clara Natoli1,2, and Stefano Iacobelli1,2

Abstract
Accumulating evidence indicates that serum and tissue levels of lectin, galactoside-binding soluble 3 binding protein (LGALS3BP), a secreted glycoprotein, are elevated in human cancers. Recently, we have identified LGALS3BP as a factor capable of stimulating angiogenesis of microvascular endothelial cells in vitro as well as in vivo. However, the potential therapeutic implications of LGALS3BP function blockade have not been explored yet. Here, we tested the ability of an anti-LGALS3BP mouse monoclonal antibody, SP-2, to antagonize LGALS3BP-induced angiogenesis and tumor growth. The antibody was found to inhibit endothelial cell tubulogenesis induced by either conditioned medium of breast cancer and melanoma cells or human recombinant LGALS3BP. In addition, SP-2 inhibited phosphorylation of FAK and its recruitment to membrane sites as well as AKT and ERK phosphorylation promoted by LGALS3BP. When used in vivo, the antibody restrained LGALS3BP-stimulated angiogenesis and growth of tumor xenografts. Furthermore, the combination of SP-2 and low-dose bevacizumab was more effective than either agent alone. Taken together, these results lead to consideration of SP-2 as a promising candidate for LGALS3BP-targeted therapy. Mol Cancer Ther; 13(4); 916–25. ©2014 AACR.
antibiotics (Sigma Aldrich Corporation). The human umbilical vein endothelial cells (HUVEC) were purchased in 2012 from Lonza and maintained in EBM-2 Medium (Lonza) containing 10% heat-inactivated FBS supplemented with EGM-2 singlequots (Lonza).

All cells were maintained at 37°C in a humidified chamber with 95% air and 5% CO₂.

The generation of MDA-MB-231 and IR-8 cells silenced for LGALS3BP (shLGALS3BP) or not (shCTR), was performed in 2012 as previously described (8). For collection of the conditioned medium, cells were grown until 80% confluent, washed with PBS, and cultured in serum-free medium for additional 24 to 48 hours. Conditioned medium was collected, centrifuged at 1,200 rpm for 15 minutes, aliquoted under sterile conditions and frozen at −80°C until use.

All cell lines were maintained in liquid nitrogen and before each experiment were passaged for fewer than 4 weeks after resuscitation. Moreover, all cell lines were mycoplasma free, as assessed by Hoechst 33342 Fluorescent Stain (Thermo Scientific) and PCR analysis.

**Recombinant LGALS3BP**

Recombinant human LGALS3BP was immunoaffinity purified (11) from serum-free supernatant of human embryonic kidney EBNA-293 cells (Invitrogen) transfected with LGALS3BP cDNA (1), as previously described (8). SDS-PAGE showed a major band (90%) migrating at approximately 97 kDa. The endotoxin level of the final purification, animals harboring MDA-MB-231 cells were injected intraperitoneally with SP-2 (15 mg/kg) or PBS on alternate days for a total of 4 injections. In other experiments, mice were implanted subcutaneously with 0.5 mL Matrigel containing either 5 × 10⁵ MDA-MB-231 cells or PBS; starting the day after implantation, animals harboring MDA-MB-231 cells were injected intraperitoneally on alternate days with either SP-2 (15 mg/kg), bevacizumab (Roche, 2 mg/kg) or a combination of SP-2 (15 mg/kg) and bevacizumab (2 mg/kg) for a total of 4 injections. Six animals per group were used. Ten days after implantation, animals were sacrificed, plugs removed, photographed, and their hemoglobin content assayed using the Drabkin method (ref. 14; Drabkin reagent kit 525, Sigma Aldrich Corporation).

**Western blotting**

Cells were lysed with radioimmunoprecipitation buffer containing protease and phosphatase inhibitors (Sigma Aldrich Corporation). Lysates were clarified by centrifugation at 14,000 rpm for 15 minutes at 4°C, subjected to 10% SDS-PAGE and Western blotting using specific antibodies against rabbit P-FAK Tyr397, P-ERK1/2 Thr202/Tyr204 (Cell Signaling Technology) or mouse actin (Sigma Aldrich Corporation).
Incubation was performed overnight at 4°C. After washing with PBS containing 0.1% Tween-20, blots were incubated with HRP-conjugated IgG secondary antibodies (Bio-Rad) at room temperature for 2 hours and developed with a chemiluminescence detection system (Perkin-Elmer).

**Tumor xenografts**

The following human tumor cell lines were implanted subcutaneously into the right flank of athymic female CD-1\textsuperscript{nu/nu} mice (6 weeks old; 25 g each; Charles River Laboratories): MDA-MB-231 (breast cancer), SKOV-3 (ovarian cancer), IR-8 and MEL-8863 (melanoma). When tumors became palpable (approximately 50–100 mm\textsuperscript{3}), animals implanted with the different cell lines (each at 5 × 10\textsuperscript{6} cells) were randomly divided into two groups of 10 animals: one group was treated intraperitoneally twice a week with either SP-2 (15 mg/kg), bevacizumab (2 mg/kg), a combination of both, or mouse IgG (15 mg/kg; as a control group). Tumor volume was monitored twice a weekly with a caliper and calculated using the following formula:

\[
\text{tumor volume (mm}^3\text{)} = \frac{\text{length} \times \text{width}^2}{2}
\]

Animal studies were approved by the local Institutional Animal Ethics Committee.

**Immunohistochemistry**

Cryostat sections (6 \textmu m) of tumor xenografts were fixed in ice-cold acetone for 10 minutes. Blood vessels were identified by incubating sections with a mixture of rat antibodies, one against mouse CD31 (PECAM-1, BD Pharmingen) and the other against mouse CD105 (endoglin).
Goat anti-rat IgG was used as a secondary antibody (Jackson IR). Following incubation with avidin–biotin–alkaline phosphatase complex (ABC-AP, Thermo Scientific), the reaction was visualized using Vulcan Fast RED (Biocare Medical) as a chromogen. Slides were counterstained with CAT hematoxylin (Biocare Medical). Positive controls were stained in parallel. Omission of the primary antibody was used as a negative control. Immunoreactive microvessels were counted by one pathologist (R. Lattanzio) at 400× magnification (0.17 mm²) in 4 different areas characterized by the greatest number of intratumoral microvessels (hotspots) and averaged for each tumor.

Statistical analysis
Data are expressed as mean ± SEM and differences among groups were determined using one-way ANOVA analysis. Mean differences in vessel counts between tumors from animals treated with SP-2 or mouse IgG were compared with the use of the paired t test. The 0.05 level of probability was used as the criterion of significance. Mann–Whitney test was used to compare the efficacy of treatments in xenograft experiments.

Results
SP-2 inhibits tube formation induced by LGALS3BP
We previously reported that human recombinant LGALS3BP was able to enhance tube formation by a direct stimulation of HUVECs (8). Here, we confirm and extend this finding by showing that tube formation was stimulated at a protein concentration as low as 0.5 μg/mL (Fig. 1A). SP-2 (40 μg/mL) inhibited LGALS3BP-induced tube formation by approximately 50% (Fig. 1B). Sp-2 alone showed any effect on tube formation (data not shown).

To evaluate whether native LGALS3BP was also effective, tube formation assay was performed in the presence of conditioned medium of MDA-MB-231 breast cancer and IR-8 melanoma cells. HUVECs suspended in either EBM-2 medium, or conditioned medium of shCTR cells, or shLGALS3BP cells, or shCTR cells treated with SP-2 (40 μg/mL), were seeded at 5 × 10⁴ cells per well in Matrigel-coated chamber slides. VEGF (50 ng/mL) was used as a positive control. Pictures show representative phase-contrast photographs of capillary-like structures taken after 4 hours from seeding. Histograms show quantification of tube formation. Data represent mean ± SD of three independent experiments. *, P < 0.001.
SP-2 counteracts LGALS3BP-induced FAK activation, αvβ3 membrane clustering, and actin remodeling

Confirming previous findings (8), exposure of HUVEC to recombinant LGALS3BP resulted in enhanced FAK phosphorylation and translocation to membrane sites (Fig. 3A). Here, we further demonstrate that LGALS3BP induced phosphorylation of FAK, AKT, and ERK (Fig. 3B and C) and that these effects were markedly reduced when cells were coexposed to SP-2 (Fig. 3A–C). Promotion of tube formation by recombinant LGALS3BP may involve binding of the protein to its endogenous ligand, galectin-3, followed by crosslinking and clustering of integrin αvβ3 on the surface of endothelial cells (15). This hypothesis was confirmed by results of Fig. 4 showing that exposure of HUVEC to recombinant LGALS3BP was accompanied by αvβ3 membrane clustering and promotion of lamellipodia formation; this effect was inhibited by coincubation with SP-2.

FAK activation by integrins is involved in actin remodeling and endothelial cell migration (16). Therefore, we sought to determine whether SP-2 could antagonize LGALS3BP-induced actin remodeling. Exposure of HUVEC to LGALS3BP was associated with actin membrane recruitment in lamellipodia, whereas the presence of these structures decreased when HUVEC were coincubated with SP-2 (Fig. 4).

The in vivo antiangiogenic effect of SP-2 is potentiated by bevacizumab

Previously, we found that silencing of LGALS3BP in MDA-MB-231 cells impaired breast cancer cell to induce blood vessels formation in vivo (8). To explore the inhibitory effect of SP-2 on LGALS3BP-induced angiogenesis in vivo, we first tested the ability of recombinant LGALS3BP to directly stimulate blood vessel formation in the Matrigel plug assay. To this end, nude mice were injected subcutaneously with Matrigel mixed with different concentrations of LGALS3BP or PBS. As shown in Fig. 5A, LGALS3BP increased blood vessel formation in a dose-dependent fashion, reaching similar effect to that induced by VEGF as evaluated by determining the hemoglobin content of the plugs.

To assess the effect of SP-2, nude mice bearing plugs containing LGALS3BP (30 μg) were injected intraperitoneally with SP-2 (15 mg/kg) or PBS on alternate day for a total of 4 injections. As shown in Fig. 5B, plugs derived from SP-2-treated animals exhibited a reduced angiogenic response compared with plugs derived from PBS-treated mice.

Figure 3. SP-2 inhibits LGALS3BP-induced cell signalling activation. A, HUVEC (5 x 10^4 cells/well) were seeded on glass coverslips and maintained in EBM-2 medium in the absence (control) or presence of LGALS3BP (10 μg/mL) alone or in combination with SP-2 (40 μg/mL) for 10 minutes. Cells were then fixed and processed for immunofluorescence. Staining of P-FAK Tyr397 (green), actin (red), and nuclei (blue) was observed using a confocal microscope. Representative photographs are shown. Arrows indicate P-FAK membrane recruitment. B, HUVECs were exposed to LGALS3BP (10 or 20 μg/mL) alone or in the presence of SP-2 (20 or 40 μg/mL) for 10 minutes. Cell lysates were subjected to Western blot analysis to detect FAK, AKT, ERK phosphorylation. Actin was used as an internal loading control. Representative Western blots are shown. C, histograms represent band intensity ratio of P-FAK/actin, P-AKT/actin, and P-ERK/actin, respectively, as measured by Image J software.
These data demonstrate that SP-2 is able to inhibit LGALS3BP-induced formation of blood vessel in vivo, supporting the hypothesis that the antibody may function as an efficient antiangiogenic agent.

To compare the effect of SP-2 with that of bevacizumab, nude mice implanted with plugs containing MDA-MB-231 cells which secrete high levels of both LGALS3BP and VEGF (8) were injected intraperitoneally with SP-2 (15 mg/kg), bevacizumab (2 mg/kg) or a combination of SP-2 and bevacizumab. The dose of bevacizumab (2 mg/kg) was chosen as the one sufficient to almost completely abolish angiogenesis induced by standard doses (100 ng) of VEGF in preliminary experiments (data not shown). As shown in Fig. 5C, the antiangiogenic effect of SP-2 was comparable with that of bevacizumab. Remarkably, the combination of SP-2 and bevacizumab was more effective than either agent alone, resulting in a nearly complete inhibition of angiogenesis.

SP-2 restrains tumor growth and its effect is potentiated by bevacizumab

To evaluate the effect of SP-2 on tumor growth, we employed tumor xenograft models grown in nude mice. Compared with the IgG control group, the administration of SP-2 (15 mg/kg i.p. twice a week) resulted in a significant delay in tumor growth (395 mm³ vs. 85 mm³; P < 0.007 for MDA-MB-231 and 411 mm³ vs. 233 mm³; P < 0.043 for IR-8; Fig. 6A and B).

The same effects were seen in tumor xenografts derived from ovarian cancer SKOV-3 cells and melanoma MEL-8863 cells (Supplementary Fig. S1).

Moreover, tumors from SP-2-treated animals showed reduced angiogenesis compared with control group, as estimated by counting the number of CD31/CD105-positive microvessels (17.3 vs. 22 for MDA-MB-231; 13.2 vs. 16.1 for IR-8; Fig. 6C and D).

To evaluate whether treatment with SP-2 plus low-dose bevacizumab leads to better tumor inhibition compared with SP-2 or bevacizumab treatment alone, we injected MBA-MB-231 cells into nude mice. Starting 3 days from cell implantation, mice were injected intraperitoneally with SP-2 (15 mg/kg), bevacizumab (2 mg/kg), SP-2 plus bevacizumab or with mouse IgG (15 mg/kg), as a control. Compared with the IgG control group, SP-2–treated mice showed significantly reduced tumor volumes (600 mm³ vs. 287 mm³; P < 0.005); the low-dose bevacizumab-treated mice did not show significantly reduced tumor volumes (600 mm³ vs. 358 mm³; P = 0.057) and tumor volumes for mice treated with SP-2 plus bevacizumab were reduced significantly (600 mm³ vs. 169 mm³; P < 0.001). Furthermore, mice injected with SP-2 plus bevacizumab had significantly reduced tumor volumes compared with SP-2–treated mice (169 mm³ vs. 287 mm³; P = 0.048; Fig. 6E).

Discussion

Tumor angiogenesis is an integral part of solid tumor development resulting from the imbalance between proangiogenic and antiangiogenic factors (17). However, much more remains to be understood about the molecular nature of unidentified factors that have the ability to promote angiogenesis in the development of human cancers.

LGALS3BP has an emerging role in tumor progression and development of metastasis (18). Elevated expression levels of LGALS3BP have been found in the large majority of solid human tumors. Several groups have reported that...
high LGALS3BP levels in serum or tumor tissue of patients with cancer correlate with a poor survival or a more advanced disease in breast cancer (4), lung cancer (7), prostatic cancer (19), hepatocarcinoma (20), melanoma (21), and non-Hodgkin lymphoma (5).

Recently, we have found that LGALS3BP secreted by human breast cancer cells functions as a proangiogenic factor through a dual mechanism, that is, induction of VEGF by tumor cells and stimulation of endothelial cells tubulogenesis, in a VEGF-independent manner (8).

In this study, we demonstrated that SP-2, a monoclonal antibody directed against LGALS3BP, was able to antagonize LGALS3BP-induced endothelial cells tubulogenesis in vitro and angiogenesis in vivo. Moreover, in Matrigel plugs containing MDA-MB-231 human breast cancer cells, SP-2 was able to inhibit angiogenesis to the same extent of bevacizumab. Noteworthy, the addition of SP-2 to bevacizumab resulted in a greater angiogenesis suppression than either agent alone. This observation indicated that, in MDA-MB-231 model, the
angiogenesis is mainly due to secreted LGALS3BP and VEGF, whose activities are inhibited by SP-2 and bevacizumab, respectively. The molecular mechanism underlying the proangiogenic effects of LGALS3BP is not completely understood. In a previous article (8), we proposed that extracellular LGALS3BP docks galectin-3 molecules resulting in cross-linking and clustering of integrins on the surface of endothelial cells. This leads to activation of FAK-mediated signaling pathways that modulate the angiogenic cascade. Here, we show that LGALS3BP induces clustering of integrin αvβ3 and actin recruitment in lamellipodia, processes that are necessary for functional connection between focal adhesion and actin cytoskeleton needed to drive cell migration (16). Furthermore, enhanced phosphorylation of AKT and ERK was observed following exposure of HUVEC to LGALS3BP. All these effects were inhibited by SP-2. Because this antibody recognizes a
conformational epitope of the lectin binding domain of LGALS3BP (10), it could be argued that SP-2 hampers formation of LGALS3BP-galectin-3 complex, preventing integrin clustering at the surface of endothelial cells.

The effect of SP-2 on tumor growth was also assessed in this study. Although the antibody did not affect tumor cell growth in vitro (data not shown), it led to a significant growth delay in several xenograft models, including melanoma, breast, and ovarian carcinoma.

The therapeutic activity of SP-2 is particularly relevant in melanoma, which is often resistant to currently available therapies and frequently overexpresses LGALS3BP (21). Thus, potential future therapeutic application of SP-2 might be explored in this malignancy.

Of note, tumors from SP-2–treated animals displayed a reduced number of blood vessels as evidenced by CD31/CD105 staining, indicating that the antibody targets tumor vasculature in vivo.

LGALS3BP expression detected by SP-2 was stronger in tumor cells, while it was little or not observed in normal human tissues. On these substrates, the antibody produced a cytoplasmic staining pattern limited to myoepithelial cells of the mammary gland, proximal tubules, and median layer of blood vessels of the kidney, some ducts, and acinar structures of the pancreas, and keratinocytes of the skin with absence of positivity of the cardiac muscle (Natali and colleagues, in preparation), thus suggesting low levels of toxicity if the antibody is administered to humans.

In current cancer therapy, particular attention has been devoted to antiangiogenic drugs, such as anti-VEGF antibody (bevacizumab) and VEGF receptor tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib; ref. 22). However, the benefits of these agents appear to be transitory, as drug resistance, tumor regrowth, and extensive vascular recovery, rapidly develop once the therapy is terminated (23–25). It would be quite interesting to investigate whether LGALS3BP plays an active role in these evasion responses.

Our data indicate that SP-2 halted tumor growth and angiogenesis. More importantly, SP-2 has activity comparable with that of bevacizumab, and when these agents are given in combination, they were more effective in suppressing angiogenesis and tumor growth, thus pointing out new possibilities for therapeutic intervention.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: S. Traini, E. Piccolo, N. Tinari, C. Natali, S. Iacobelli
Development of methodology: S. Traini, R. La Sorda, M. D’Egidio, A. Di Riccardo
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C. Rossi, R. La Sorda, F. Spinella, A. Bagno, M. Piantelli
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Traini, N. Tinari, F. Spinella, A. Bagno, R. Lattanzio, A. Grassadonia, M. Piantelli
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M. Piantelli
Writing, review, and/or revision of the manuscript: S. Traini, E. Piccolo, N. Tinari, R. Lattanzio, F. Tomao, A. Grassadonia, S. Iacobelli
Study supervision: N. Tinari, R. Lattanzio, C. Natali, S. Iacobelli

Grant Support
This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of University and Education (MUR) of Italy (2011–2012; to S. Iacobelli).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 26, 2012; revised November 18, 2013; accepted February 12, 2014; published OnlineFirst February 19, 2014.

References
Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti-Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody

Sara Traini, Enza Piccolo, Nicola Tinari, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-12-1117

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2014/02/19/1535-7163.MCT-12-1117.DC1

Cited articles
This article cites 25 articles, 9 of which you can access for free at:
http://mct.aacrjournals.org/content/13/4/916.full.html#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/13/4/916.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.